AR085056A1 - Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion - Google Patents

Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion

Info

Publication number
AR085056A1
AR085056A1 ARP120100317A ARP120100317A AR085056A1 AR 085056 A1 AR085056 A1 AR 085056A1 AR P120100317 A ARP120100317 A AR P120100317A AR P120100317 A ARP120100317 A AR P120100317A AR 085056 A1 AR085056 A1 AR 085056A1
Authority
AR
Argentina
Prior art keywords
preparation
espiro
iloxi
metoxi
undecan
Prior art date
Application number
ARP120100317A
Other languages
English (en)
Inventor
Waldemar Pfrengle
Guenther Huchler
Markus Ostermeier
Peter Sieger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR085056A1 publication Critical patent/AR085056A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de la fórmula (1), que muestra propiedades farmacológicas, en particular un efecto inhibidor sobre la transducción de señales mediada por tirosina quinasas, un procedimiento para la preparación estereoselectiva de estos compuestos, en particular para la inhalación de formulaciones farmacéuticas adecuadas y su uso para el tratamiento de enfermedades, en particular enfermedades tumorales, de la hiperplasia benigna de la próstata, así como de enfermedades del pulmón y de las vías respiratorias.
ARP120100317A 2011-02-01 2012-01-31 Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion AR085056A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11152895 2011-02-01

Publications (1)

Publication Number Publication Date
AR085056A1 true AR085056A1 (es) 2013-08-07

Family

ID=43896655

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100317A AR085056A1 (es) 2011-02-01 2012-01-31 Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion

Country Status (23)

Country Link
US (2) US8853225B2 (es)
EP (1) EP2670736B1 (es)
JP (1) JP2014504619A (es)
KR (1) KR20140011330A (es)
CN (1) CN103608336A (es)
AP (1) AP3531A (es)
AR (1) AR085056A1 (es)
AU (1) AU2012213556A1 (es)
BR (1) BR112013019416A2 (es)
CA (1) CA2826193A1 (es)
CL (1) CL2013002031A1 (es)
CO (1) CO6781555A2 (es)
EA (1) EA023573B1 (es)
EC (1) ECSP13012847A (es)
GE (1) GEP20156423B (es)
IL (1) IL227534A0 (es)
MA (1) MA34845B1 (es)
MX (1) MX2013008870A (es)
PE (1) PE20141012A1 (es)
SG (1) SG192216A1 (es)
TN (1) TN2013000323A1 (es)
UY (1) UY33889A (es)
WO (1) WO2012104206A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289881A1 (de) 2009-08-06 2011-03-02 Boehringer Ingelheim International GmbH Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen
EA023573B1 (ru) 2011-02-01 2016-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Дималеат 9-[4-(3-хлор-2-фторфениламино)-7-метоксихиназолин-6-илокси]-1,4-диазаспиро[5.5]ундекан-5-она, его применение в качестве лекарственного средства и его получение
AU2013218119A1 (en) 2012-02-09 2014-07-17 Boehringer Ingelheim International Gmbh Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro [5.5] undecanes
WO2014012859A1 (en) * 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
KR101847757B1 (ko) 2013-12-12 2018-05-28 톈진 헤메이 파마슈티칼 사이-테크 캄파니 리미티드 퀴나졸린 유도체
CN105017164A (zh) * 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 含新型苯并喹唑啉和邻位氯结构的酪氨酸激酶抑制剂及用途
CN105130913A (zh) * 2015-08-25 2015-12-09 佛山市赛维斯医药科技有限公司 一类多取代的苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN109485648A (zh) * 2018-12-17 2019-03-19 无锡合全药业有限公司 叔丁基-1-甲基-5-氧亚基三氮杂螺[5.5]十一烷-8-甲酸基酯的制备方法
CN109608470A (zh) * 2018-12-17 2019-04-12 上海药明康德新药开发有限公司 叔丁基-9-氧亚基-2,5,8-三氮杂螺[3.5]壬烷-2-甲酸基酯的合成方法
CN109503579A (zh) * 2018-12-17 2019-03-22 天津药明康德新药开发有限公司 叔丁基-1-甲基-5-氧亚基三氮杂螺[5.5]十一烷-9-甲酸基酯的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
BR0308902A (pt) * 2002-03-30 2005-01-04 Boehringer Ingelheim Pharma 4-(n-fenilamino)-quinazolinas/quinolinas como inibidoras da tirosina cinase
CN101061112A (zh) 2004-09-17 2007-10-24 Osi制药公司 作为c－Kit原癌基因抑制剂的（螺环基酰氨基）氨基噻吩化合物
AU2006326157A1 (en) 2005-12-12 2007-06-21 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof
SI2202216T1 (sl) 2007-10-26 2012-10-30 Japan Tobacco Inc Spiro obročna spojina in njena uporaba za medicinske namene
WO2009098061A1 (de) * 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CA2735875A1 (en) * 2008-09-03 2010-03-11 Boehringer Ingelheim International Gmbh Use of quinazoline derivatives for the treatment of viral diseases
EP2289881A1 (de) * 2009-08-06 2011-03-02 Boehringer Ingelheim International GmbH Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen
EA023573B1 (ru) 2011-02-01 2016-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Дималеат 9-[4-(3-хлор-2-фторфениламино)-7-метоксихиназолин-6-илокси]-1,4-диазаспиро[5.5]ундекан-5-она, его применение в качестве лекарственного средства и его получение

Also Published As

Publication number Publication date
EP2670736B1 (de) 2017-03-15
JP2014504619A (ja) 2014-02-24
AU2012213556A1 (en) 2013-08-22
UY33889A (es) 2012-08-31
ECSP13012847A (es) 2014-09-30
MA34845B1 (fr) 2014-01-02
EP2670736A1 (de) 2013-12-11
EA201300872A1 (ru) 2014-01-30
US20140371226A1 (en) 2014-12-18
WO2012104206A1 (de) 2012-08-09
PE20141012A1 (es) 2014-09-10
CO6781555A2 (es) 2013-10-31
SG192216A1 (en) 2013-09-30
EA023573B1 (ru) 2016-06-30
GEP20156423B (en) 2016-01-11
CL2013002031A1 (es) 2013-12-27
TN2013000323A1 (en) 2015-01-20
US20130030003A1 (en) 2013-01-31
CA2826193A1 (en) 2012-08-09
AP2013006989A0 (en) 2013-07-31
US8853225B2 (en) 2014-10-07
KR20140011330A (ko) 2014-01-28
US8906931B1 (en) 2014-12-09
AP3531A (en) 2016-01-13
WO2012104206A9 (de) 2013-11-21
IL227534A0 (en) 2013-09-30
MX2013008870A (es) 2013-08-14
NZ613917A (en) 2015-08-28
BR112013019416A2 (pt) 2019-09-24
CN103608336A (zh) 2014-02-26

Similar Documents

Publication Publication Date Title
AR085056A1 (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
DOP2010000012A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
DOP2012000063A (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
ECSP109934A (es) Compuesto - 946
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CR20130617A (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
TN2014000175A1 (en) Novel purine derivatives and their use in the treatment of disease
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
ECSP10010328A (es) Heterociclos espirocíclicos, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparación.
MX2013002384A (es) Compuestos quinazolina y metodos para utilizarlos.
MX336332B (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
WO2012030914A8 (en) 4-azolylaminoquinazoline derivatives and methods of use thereof
EA201491651A1 (ru) Новые соединения для лечения дислипидемии и родственных заболеваний
UY32830A (es) Procedimientos para la sintesis estereoselectiva de heterocíclos bicíclicos
UY30934A1 (es) Producto farmacéutico combinacion de un antagonista del receptor de quimioquina 1 (ccr1) y un antagonista muscarinico, composiciones farmacéuticas y aplicaciones.
EA201400786A1 (ru) Карбоциклические нуклеозиды, их фармацевтическое применение и композиции
AR080176A1 (es) Sales e hidratos de la 4-((3-cloro-4-fluoro-fenil)amino)-6-(cis-4-(n-((morf-1-olin-4-il)carbonil)-n-metil-amino)-ciclohexan-1-iloxi)-7-metoxi-quinazolina, su uso como medicamento y su preparacion
BR112017003880A2 (pt) derivados de poliéteres de n-aril-triciclopirimidina-2-amina macrocíclicos como inibidores de ftl3 e jak
UY31983A (es) Heterociclos espirocíclicos, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparación
CY1115157T1 (el) Παραγωγα κιναζολινης ρυθμιστικα της κινασης jak και μεθοδοι χρησεως αυτων

Legal Events

Date Code Title Description
FB Suspension of granting procedure